Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Redhill Biopharma Ltd RDHL

Healthcare

RedHill Biopharma Ltd is an Israel-based specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204... see more

Add To Watchlist

Recent & Breaking News (NDAQ:RDHL)

RedHill Biopharma and IntelGenx Announce Marketing Approval of RIZAPORT® for Migraines in Luxembourg

GlobeNewswire April 13, 2017

RedHill Biopharma Announces Exclusive U.S. License from Entera Health for Commercial GI Product EnteraGam®

GlobeNewswire April 5, 2017

RedHill Biopharma Receives FDA Orphan Drug Designation for YELIVA® for the Treatment of Cholangiocarcinoma

GlobeNewswire April 4, 2017

RedHill Biopharma to Present at BioCentury Future Leaders in the Biotech Industry Conference

GlobeNewswire March 30, 2017

RedHill Biopharma to Present at the 2017 MAP Conference

GlobeNewswire March 22, 2017

RedHill Biopharma Announces First Patient Dosed in the Open-Label Extension Study to the Phase III Study with RHB-104 for Crohn’s Disease

GlobeNewswire March 21, 2017

RedHill Biopharma to Present at the BIO-Europe Spring 2017 Conference

GlobeNewswire March 13, 2017

RedHill Biopharma’s Co-Promotion Partner Concordia Announces U.S. District Court Grants Treble Damages Relating to Donnatal®

GlobeNewswire March 7, 2017

RedHill Biopharma Announces Availability of Its Annual Report on Form 20-F Through Its Website

GlobeNewswire February 23, 2017

RedHill Biopharma Reports 2016 Fourth Quarter and Full-Year Financial Results

GlobeNewswire February 23, 2017

RedHill Biopharma Completes Treatment of Last Patient in BEKINDA® Phase III Study for Acute Gastroenteritis

GlobeNewswire February 21, 2017

RedHill Biopharma to Host Fourth Quarter and Full-Year 2016 Financial Results Conference Call on February 23, 2017

GlobeNewswire February 16, 2017

RedHill Biopharma Announces Enrollment of Last Patient in BEKINDA® Phase III Study for Acute Gastroenteritis

GlobeNewswire February 13, 2017

RedHill Biopharma to Present at the BIO CEO & Investor Conference

GlobeNewswire February 6, 2017

20 Stocks Moving In Monday's Pre-Market Session

Benzinga.com January 23, 2017

RedHill Biopharma Provides 2017 Semi-Annual Business Update

GlobeNewswire January 12, 2017

RedHill Biopharma Announces QIDP Fast-Track Designation Granted by FDA to RHB-104 for Nontuberculous Mycobacteria Infections

GlobeNewswire January 11, 2017

RedHill Biopharma Announces First Dosing in RHB-105 Supportive PK Studies Ahead of Confirmatory Phase III Study for H. pylori Infection

GlobeNewswire January 10, 2017

RedHill Biopharma’s RHB-105 Positive Phase III Study Results for H. pylori Infection Presented at the Innovations in Gastroenterology 2017 Symposium

GlobeNewswire January 9, 2017

RedHill Biopharma Announces Exercise of Stock Options by Directors and Senior Management

GlobeNewswire January 9, 2017